Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.

MLA

Wetz, Christoph, et al. “Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.” Cancers, vol. 15, no. 24, Dec. 2023, p. 5717. EBSCOhost, https://doi.org/10.3390/cancers15245717.

APA

Wetz, C., Ruhwedel, T., Schatka, I., Grabowski, J., Jann, H., Metzger, G., Galler, M., Amthauer, H., & Rogasch, J. M. M. (2023). Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. Cancers, 15(24), 5717. https://doi.org/10.3390/cancers15245717

Chicago

Wetz, Christoph, Tristan Ruhwedel, Imke Schatka, Jane Grabowski, Henning Jann, Giulia Metzger, Markus Galler, Holger Amthauer, and Julian M. M. Rogasch. 2023. “Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.” Cancers 15 (24): 5717. doi:10.3390/cancers15245717.